iTeos Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
iTeos Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2019 to Q2 2024.
  • iTeos Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $8.06M, a 15.8% increase year-over-year.
  • iTeos Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $29.6M, a 21.3% increase year-over-year.
  • iTeos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $27M, a 25.3% increase from 2022.
  • iTeos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $21.6M, a 56.3% increase from 2021.
  • iTeos Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $13.8M, a 221% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $29.6M $8.06M +$1.1M +15.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $28.5M $7.26M +$1.46M +25.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-10
Q4 2023 $27M $7.19M +$1.31M +22.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 $25.7M $7.06M +$1.33M +23.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $24.4M $6.96M +$1.2M +20.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $23.2M $5.81M +$1.61M +38.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q4 2022 $21.6M $5.89M +$1.84M +45.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 $19.7M $5.72M +$1.78M +45.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $17.9M $5.76M +$2.53M +78.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $15.4M $4.19M +$1.61M +62.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $13.8M $4.04M +$2M +97.9% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 $11.8M $3.94M +$2.23M +130% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $9.57M $3.23M +$2.88M +822% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $6.69M $2.58M +$2.4M +1289% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $4.29M $2.04M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-23
Q3 2020 $1.71M +$1.51M +753% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $350K +$147K +72.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 $186K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q3 2019 $201K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $203K Apr 1, 2019 Jun 30, 2019 10-Q 2020-09-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.